Jia Tian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jia Tian has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Weian Zhang
Shanghai Key Laboratory of Functional Materials Chemistry East China University of Science and Technology Shanghai China
48 shared publications Baoxuan Huang
Shanghai Key Laboratory of Functional Materials Chemistry, School of Chemistry and Molecular Engineering, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China
22 shared publicationsWenlong Huang
7 shared publicationsGuoliang Yang
School of Materials Science and Engineering East China University of Science and Technology Shanghai 200237 China
6 shared publications- Hongliang Cao
School of Materials Science and Engineering East China University of Science and Technology Shanghai China
6 shared publications Lei Xia
Shanghai Key Laboratory of Functional Materials Chemistry East China University of Science and Technology Shanghai 200237 China
6 shared publications
Latest Publications
- 31 August 2026
- Published by Elsevier in Biomaterials
- Vol. 338
An intelligent phototheranostic nanoplatform for controllable FRET-activated NIR-II imaging-guided phototherapy
- 31 August 2026
- Published by Elsevier in Biomaterials
- Vol. 338
An intelligent phototheranostic nanoplatform for controllable FRET-activated NIR-II imaging-guided phototherapy
- 15 May 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 217, 680-696
A cascade-responsive nanoplatform for cyclooxygenase-2 inhibition and inflammation regulation to enhance photoimmunotherapy
- 15 May 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 217, 680-696
A cascade-responsive nanoplatform for cyclooxygenase-2 inhibition and inflammation regulation to enhance photoimmunotherapy
- 1 May 2026
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (6) , 3919-3932
Unimolecular Photodynamic Nanoassembly for Amplified Photoimmunotherapy via Expanded ROS Generation and Hypoxia Reversal
Photodynamic therapy (PDT), a promising noninvasive antitumor therapeutic approach, can directly kill cancer cells and trigger an immunogenic cell death (ICD) effect by generating reactive oxygen species (ROS) and the cascade reactions of antitumor immunity. However, the hypoxic tumor microenvironment severely compromises the efficacy of PDT. To address this challenge, a self-oxycarrying nanoassembly POFF integrating the Type-I NIR photosensitizer tetrafluorophenyl bacteriochlorin (FBC) and an oxygen-carrying perfluorocarbon moiety was developed for amplified photoimmunotherapy via expanded ROS generation and hypoxia reversal. The nanoassembly exhibited "self-oxycarrying" capability and both enhanced Type-I and Type-II photodynamic performance to effectively alleviate hypoxia. Furthermore, in vitro and in vivo studies demonstrated that POFF possessed potent antitumor activity upon 750 nm laser light irradiation. The PDT-induced destruction of cancer cells released tumor-associated antigens, which, in turn, triggered a robust antitumor immune response and promoted the eradication of residual malignant cells. Collectively, this nanoassembly not only ameliorates the hypoxic tumor microenvironment but also provides a promising strategy to amplify the efficacy of photodynamic immunotherapy.
- 1 May 2026
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (6) , 3919-3932
Unimolecular Photodynamic Nanoassembly for Amplified Photoimmunotherapy via Expanded ROS Generation and Hypoxia Reversal
Photodynamic therapy (PDT), a promising noninvasive antitumor therapeutic approach, can directly kill cancer cells and trigger an immunogenic cell death (ICD) effect by generating reactive oxygen species (ROS) and the cascade reactions of antitumor immunity. However, the hypoxic tumor microenvironment severely compromises the efficacy of PDT. To address this challenge, a self-oxycarrying nanoassembly POFF integrating the Type-I NIR photosensitizer tetrafluorophenyl bacteriochlorin (FBC) and an oxygen-carrying perfluorocarbon moiety was developed for amplified photoimmunotherapy via expanded ROS generation and hypoxia reversal. The nanoassembly exhibited "self-oxycarrying" capability and both enhanced Type-I and Type-II photodynamic performance to effectively alleviate hypoxia. Furthermore, in vitro and in vivo studies demonstrated that POFF possessed potent antitumor activity upon 750 nm laser light irradiation. The PDT-induced destruction of cancer cells released tumor-associated antigens, which, in turn, triggered a robust antitumor immune response and promoted the eradication of residual malignant cells. Collectively, this nanoassembly not only ameliorates the hypoxic tumor microenvironment but also provides a promising strategy to amplify the efficacy of photodynamic immunotherapy.
- 28 April 2026
- Published by American Chemical Society (ACS) in ACS Macro Letters
- Vol. 15 (5) , 762-770
Polymannose-Guided Repolarization of Tumor-Associated Macrophages for Enhanced Photodynamic Immunotherapy
Photodynamic immunotherapy has been recognized as a promising strategy for malignant tumor treatment, but its efficacy is still limited by the immunosuppressive tumor microenvironment (TME), particularly the dominance of M2-like tumor-associated macrophages (TAMs). To overcome this limitation, we constructed an acid-responsive, mannose-functionalized nanoplatform (FI@PMD) to target the TAMs. FI@PMD efficiently accumulates in tumors and is selectively internalized by M2-like macrophages via mannose-receptor-mediated recognition. Under acidic conditions, it undergoes structural disassociation, leading to the release of therapeutic components of a near-infrared photosensitizer (FBC) and the Toll-like receptor 7 (TLR7) agonist imiquimod (IMQ). Upon light irradiation, the released FBC could generate reactive oxygen species (ROS) that promote the polarization of TAMs from the M2 phenotype toward the M1 phenotype, thereby enabling immunosuppressive TME remodeling and enhancing photodynamic immunotherapy. In vitro studies demonstrated that FI@PMD is efficiently taken up by M2-like macrophages and induces their repolarization, accompanied by the upregulation of pro-inflammatory cytokines and the suppression of anti-inflammatory factors, resulting in inhibited tumor cell proliferation. In vivo experiments demonstrated that FI@PMD increased the infiltration of CD8+ cytotoxic T cells in tumor tissues to 2.85-fold of that in the PBS group while reducing the proportion of Treg cells to 0.86-fold. Collectively, this TAM-targeted reprogramming strategy provides a promising approach to overcome immunosuppressive TME and enhance the efficacy of photodynamic immunotherapy in malignant tumors.
- 28 April 2026
- Published by American Chemical Society (ACS) in ACS Macro Letters
- Vol. 15 (5) , 762-770
Polymannose-Guided Repolarization of Tumor-Associated Macrophages for Enhanced Photodynamic Immunotherapy
Photodynamic immunotherapy has been recognized as a promising strategy for malignant tumor treatment, but its efficacy is still limited by the immunosuppressive tumor microenvironment (TME), particularly the dominance of M2-like tumor-associated macrophages (TAMs). To overcome this limitation, we constructed an acid-responsive, mannose-functionalized nanoplatform (FI@PMD) to target the TAMs. FI@PMD efficiently accumulates in tumors and is selectively internalized by M2-like macrophages via mannose-receptor-mediated recognition. Under acidic conditions, it undergoes structural disassociation, leading to the release of therapeutic components of a near-infrared photosensitizer (FBC) and the Toll-like receptor 7 (TLR7) agonist imiquimod (IMQ). Upon light irradiation, the released FBC could generate reactive oxygen species (ROS) that promote the polarization of TAMs from the M2 phenotype toward the M1 phenotype, thereby enabling immunosuppressive TME remodeling and enhancing photodynamic immunotherapy. In vitro studies demonstrated that FI@PMD is efficiently taken up by M2-like macrophages and induces their repolarization, accompanied by the upregulation of pro-inflammatory cytokines and the suppression of anti-inflammatory factors, resulting in inhibited tumor cell proliferation. In vivo experiments demonstrated that FI@PMD increased the infiltration of CD8+ cytotoxic T cells in tumor tissues to 2.85-fold of that in the PBS group while reducing the proportion of Treg cells to 0.86-fold. Collectively, this TAM-targeted reprogramming strategy provides a promising approach to overcome immunosuppressive TME and enhance the efficacy of photodynamic immunotherapy in malignant tumors.
- Open Access
- 13 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Chemical anchoring of immunotherapeutic drugs within senescent tumor cells overcomes senescence-driven immunotherapy resistance
Multidrug resistance (MDR) compromises cancer treatment efficacy and leads to therapeutic failure. Therapy-induced senescence further complicates MDR through senescence-enhanced drug efflux and senescence-associated secretory phenotypes (SASPs), remaining a huge challenge. Here, we develop a self-generative senescence-associated β-galactosidase (SA-β-gal)-initiated chemical anchoring of lysosomal protein approach to counteract drug efflux and reprogram SASPs. A senescence-tumor-targeted immunotherapeutic drug (DN-Ghcy) is fabricated by a SA-β-gal-activatable bio-orthogonal receptor (Ghcy) and an engineered immunostimulatory prodrug (DN, an indoleamine 2,3-dioxygenase (IDO) inhibitor conjugated to a PD-L1 binding peptide). DN-Ghcy is selectively immobilized in senescent tumor cells via SA-β-gal-catalyzed bio-orthogonal nano-receptor, enabling drug retention and bypassing transporter-mediated efflux. Under near-infrared irradiation, DN-Ghcy concurrently mediates degradation of PD-L1, release of IDO inhibitor, and disruption of lysosomal integrity. This strategy reverses immunotherapy resistance in female mice with senescent tumors, establishing a promising modality to overcome senescence-driven immunotherapy resistance.
- 13 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessChemical anchoring of immunotherapeutic drugs within senescent tumor cells overcomes senescence-driven immunotherapy resistance
Multidrug resistance (MDR) compromises cancer treatment efficacy and leads to therapeutic failure. Therapy-induced senescence further complicates MDR through senescence-enhanced drug efflux and senescence-associated secretory phenotypes (SASPs), remaining a huge challenge. Here, we develop a self-generative senescence-associated β-galactosidase (SA-β-gal)-initiated chemical anchoring of lysosomal protein approach to counteract drug efflux and reprogram SASPs. A senescence-tumor-targeted immunotherapeutic drug (DN-Ghcy) is fabricated by a SA-β-gal-activatable bio-orthogonal receptor (Ghcy) and an engineered immunostimulatory prodrug (DN, an indoleamine 2,3-dioxygenase (IDO) inhibitor conjugated to a PD-L1 binding peptide). DN-Ghcy is selectively immobilized in senescent tumor cells via SA-β-gal-catalyzed bio-orthogonal nano-receptor, enabling drug retention and bypassing transporter-mediated efflux. Under near-infrared irradiation, DN-Ghcy concurrently mediates degradation of PD-L1, release of IDO inhibitor, and disruption of lysosomal integrity. This strategy reverses immunotherapy resistance in female mice with senescent tumors, establishing a promising modality to overcome senescence-driven immunotherapy resistance.
- 5 February 2026
- Published by Elsevier in Biomaterials
- Vol. 330, 124042
Lymph nodes-targeted nano-prodrug for precise B cell immunoregulation to prevent collagen-induced arthritis
- 5 February 2026
- Published by Elsevier in Biomaterials
- Vol. 330, 124042
Lymph nodes-targeted nano-prodrug for precise B cell immunoregulation to prevent collagen-induced arthritis
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
A nucleus-targeting type-I photosensitive nanoplatform for DNA-binding-enhanced photodynamic therapy
A TME-responsive nucleus-targeting DNA-binding nanoplatform for hypoxic-tumor photodynamic therapy. It combines a polymeric vehicle and AIE type-I photosensitizer (TD) for TME-specific release, causing intranuclear DNA damage and antitumor effects.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
A nucleus-targeting type-I photosensitive nanoplatform for DNA-binding-enhanced photodynamic therapy
A TME-responsive nucleus-targeting DNA-binding nanoplatform for hypoxic-tumor photodynamic therapy. It combines a polymeric vehicle and AIE type-I photosensitizer (TD) for TME-specific release, causing intranuclear DNA damage and antitumor effects.
- 29 December 2025
- Published by American Chemical Society (ACS) in ACS Macro Letters
- Vol. 15 (1) , 60-66
β-Galactosidase-Cleavable Polymeric Senotherapeutics for Protein-Binding Photodynamic Senolysis
Selective elimination of senescent cells (SnCs) through senolytic strategies can counteract the progression of age-related dysfunction, but achieving precise, broad-spectrum, and controllable senolysis remains challenging. Here, we report PG@FBC, a polymeric senotherapeutic that exploits senescence-associated β-galactosidase (SA-β-gal) to trigger supramolecular disassembly and controlled photosensitizer release, enabling photodynamic senolysis with real-time imaging. Briefly, PG@FBC is composed of an amphiphilic block copolymer, POEGMA-b-GMA (PG), synthesized via reversible addition-fragmentation chain transfer (RAFT) polymerization from hydrophilic POEGMA and SA-β-gal-cleavable hydrophobic β-GMA units. Subsequent coassembly of PG with FBC photosensitizer affords core-shell nanoparticles featuring a hydrophobic core and a hydrophilic shell, with preferential uptake by SnCs. Once localized within SnCs, overexpressed SA-β-gal cleaves the β-GMA units of PG@FBC, triggering disassembly and releasing FBC. The released FBC binds intracellular proteins to mitigate aggregation-caused quenching (ACQ), enhance solubility, and amplify ROS generation under NIR-irradiation, inducing senolysis with minimal off-target cytotoxicity. In addition, the intrinsic fluorescence of FBC provides real-time imaging capability, establishing PG@FBC as a precise theranostic platform for integrated monitoring and elimination of SnCs in senescence-associated pathologies.
- 29 December 2025
- Published by American Chemical Society (ACS) in ACS Macro Letters
- Vol. 15 (1) , 60-66
β-Galactosidase-Cleavable Polymeric Senotherapeutics for Protein-Binding Photodynamic Senolysis
Selective elimination of senescent cells (SnCs) through senolytic strategies can counteract the progression of age-related dysfunction, but achieving precise, broad-spectrum, and controllable senolysis remains challenging. Here, we report PG@FBC, a polymeric senotherapeutic that exploits senescence-associated β-galactosidase (SA-β-gal) to trigger supramolecular disassembly and controlled photosensitizer release, enabling photodynamic senolysis with real-time imaging. Briefly, PG@FBC is composed of an amphiphilic block copolymer, POEGMA-b-GMA (PG), synthesized via reversible addition-fragmentation chain transfer (RAFT) polymerization from hydrophilic POEGMA and SA-β-gal-cleavable hydrophobic β-GMA units. Subsequent coassembly of PG with FBC photosensitizer affords core-shell nanoparticles featuring a hydrophobic core and a hydrophilic shell, with preferential uptake by SnCs. Once localized within SnCs, overexpressed SA-β-gal cleaves the β-GMA units of PG@FBC, triggering disassembly and releasing FBC. The released FBC binds intracellular proteins to mitigate aggregation-caused quenching (ACQ), enhance solubility, and amplify ROS generation under NIR-irradiation, inducing senolysis with minimal off-target cytotoxicity. In addition, the intrinsic fluorescence of FBC provides real-time imaging capability, establishing PG@FBC as a precise theranostic platform for integrated monitoring and elimination of SnCs in senescence-associated pathologies.
- 19 December 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 212, 579-592
Photosensitive calcium-based nanoinducer for NIR-triggered immunogenic cell death and anti-tumor immunity
- 19 December 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 212, 579-592
Photosensitive calcium-based nanoinducer for NIR-triggered immunogenic cell death and anti-tumor immunity